Dr. John D. Goldman

Mark Sulkowski, MD, is a Professor of Medicine at the Johns Hopkins University School of Medicine and the Director of the Division of Infectious Diseases at Johns Hopkins Bayview Medical Center. He also serves as the Medical Director of the Viral Hepatitis Center in the Divisions of Infectious Diseases and Gastroenterology/Hepatology in the Department of Medicine and is the Senior Associate Dean for Clinical Trials. He received his MD from Temple University School of Medicine, Philadelphia, PA (1992), pursued training in Internal Medicine at Duke University School of Medicine, Durham, NC (1995) and completed his Fellowship in Infectious Diseases (1998) at the Johns Hopkins University School of Medicine. Prof. Sulkowski has been the principal investigator for more than 120 clinical trials related to the management of viral hepatitis B and C in persons with and without HIV co-infection. He was the global principal investigator for more than a dozen trials, including the largest clinical trial of agents for the treatment of hepatitis C (New England Journal of Medicine, 2009) and the vanguard study of combination therapy with direct inhibitors of the HCV NS5A and NS5B non-structural proteins (New England Journal of Medicine, 2014). He is the past-chair of the Hepatitis Transformative Sciences Group of the National Institute of Health-funded adult AIDS Clinical Trials Group (ACTG) where he led translational studies of liver disease, namely hepatitis B and C virus. He is an elected member of the American Society for Clinical Investigation (2011) and the American Association of Physicians (2017). Prof. Sulkowski is a member of numerous professional societies including the American Association for the Study of Liver Diseases (AASLD), the European Association for the Study of the Liver (EASL), and the Infectious Diseases Society of America (IDSA). With more than 300 peer-reviewed articles, he is widely published with works in Annals of Internal Medicine, New England Journal of Medicine, JAMA, Clinical Infectious Diseases, Journal of Hepatology, and Hepatology. In 2017, 2018 and 2019, he was named as a Highly Cited Researcher (Clarivate Analytics) defined as the being in the top 1% of global researchers in 21 fields of the sciences and social sciences based on the number of citations for papers. As an invited lecturer, he has been frequently invited to present at major national and international medical congresses and has educated learners in more than 25 countries. Dr. Sulkowski is rated as a Distinguished provider by MediFind in the treatment of Hepatitis C. His top areas of expertise are Hepatitis C, Hepatitis, HIV/AIDS, and Hepatitis B.

Dr. Christine Durand, associate professor of medicine and oncology and member of the Johns Hopkins Kimmel Cancer Center, is involved in clinical and translational research focused on individuals infected with HIV and hepatitis C virus who require cancer and transplant therapies. Her current research efforts include looking at outcomes of hepatitis C treatment after solid organ transplant, the potential use of organs from HIV-infected donors for HIV-infected solid organ transplant candidates, and HIV cure strategies including bone marrow transplantation. Dr. Durand is rated as a Distinguished provider by MediFind in the treatment of Hepatitis C. Her top areas of expertise are HIV/AIDS, Hepatitis C, Hepatitis, Tissue Biopsy, and Nephrectomy.

Dr. Andrea L. Cox is a professor of Internal Medicine at the Johns Hopkins University School of Medicine in the Division of Infectious Diseases and is a member of the Johns Hopkins Kimmel Cancer Center. She holds joint appointments in Oncology and at the Johns Hopkins Bloomberg School of Public Health, in Molecular Microbiology and Immunology. She is an internationally recognized leader in studies of immune responses in immunocompetent and immunocompromised patient populations to viral infections and vaccines against them, including SARS-Co-V-2 (the virus that causes COVID-19), HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV). Dr. Cox earned her Ph.D. in chemistry from the University of Virginia, where she characterized peptides that drive T cell responses. She then earned her M.D. and completed internal medicine residency and infectious disease fellowship training at Johns Hopkins. She leads the largest prospective cohort study of acute HCV infection, designed to enable detailed molecular analysis of HCV transmission, host immune responses, and virus sequence evolution. She co-led the first prophylactic HCV vaccine trial in individuals at risk of HCV infection. She leads a multidisciplinary international team investigating HCV-specific immune responses to improve vaccine development against HCV, is the lead immunologist on a clinical trial of HBV vaccines in people living with HIV, and co-leads a large team investigating immune responses to COVID-19 infection and vaccines. In addition to her research on viral infections and vaccines, Dr. Cox is actively involved in clinical care of patients with HCV, HIV, and HBV infections. Dr. Cox serves as the director of the Medical Scientist Training Program. A teacher, advisor, and mentor of physician-scientists and scientists, Dr. Cox mentors Ph.D. students in the Johns Hopkins Cellular and Molecular Medicine, Molecular Microbiology and Immunology, and the Immunology graduate training programs. Dr. Cox is rated as an Advanced provider by MediFind in the treatment of Hepatitis C. Her top areas of expertise are Hepatitis C, Hepatitis, COVID-19, and HIV/AIDS.